RecruitingNCT06546007

Rarecells Molecular Biomarkers for Early Detection of Lung Cancer

Clinical Study To Evaluate the Sensitivity of Circulating Iset® by Rarecells Molecular Biomarkers for Early Detection of Lung Cancer

Sponsor

Rarecells Diagnostics SAS

Enrollment

50 participants

Start Date

Nov 13, 2024

Study Type

OBSERVATIONAL

Conditions

Lung Cancer Pulmonary Neoplasm

Summary

Early diagnosis of lung cancer is a public health priority. Additionally, early detection of recurrences after treatment is crucial for optimizing disease management. This study seeks to demonstrate the accuracy of the Rarecells ISET® circulating tumor cells DNA (CTC-DNA), combined with circulating tumor DNA (ctDNA), for the early diagnosis of lung cancer.

Eligibility

Min Age: 35 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This study is collecting blood samples from people with resectable (surgically removable) lung cancer to test whether certain molecular markers in rare circulating cells can detect lung cancer early and monitor treatment response. **You may be eligible if...** - You are 35–85 years old - You have been diagnosed with lung cancer that is eligible for surgery, and have not yet received any treatment - You are able to give informed consent **You may NOT be eligible if...** - You have been previously treated for lung cancer or any other cancer - You are receiving neoadjuvant (pre-surgery) treatment - You are pregnant - Your medical records or pathology samples are incomplete Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.